NCT00978302View on ClinicalTrials.gov

Safety Study of Repeated, Escalating Doses of Intradermal Avotermin (Juvista)

PHASE1CompletedINTERVENTIONAL
Enrollment

55

Participants

Timeline

Start Date

May 31, 2001

Primary Completion Date

August 31, 2001

Study Completion Date

August 31, 2001

Conditions
CicatrixWound Healing
Interventions
DRUG

Avotermin

Intradermal injection, 50ng/100μl/3mm punch biopsy, once at time of biopsy and again 24 h later

DRUG

Avotermin

Intradermal injection, 100ng/100μl/3mm punch biopsy, once at time of biopsy and again 24 h later

DRUG

Avotermin

Intradermal injection, 500ng/100μl/3mm punch biopsy, once at time of biopsy and again 24 h later

DRUG

Avotermin

Intradermal injection, 1000ng/100μl/3mm punch biopsy, once at time of biopsy and again 24 h later

DRUG

Avotermin

Intradermal injection, 1μg/100μl/3mm punch biopsy, once at time of biopsy and again 24 h later

DRUG

Avotermin

Intradermal injection, 10μg/100μl/3mm punch biopsy, once at time of biopsy and again 24 h later

DRUG

Placebo (vehicle)

Intradermal injection at time of biopsy and again 24 h later

Trial Locations (1)

M13 9XX

Renovo Clinical Trials Unit, Manchester

All Listed Sponsors
lead

Renovo

INDUSTRY

NCT00978302 - Safety Study of Repeated, Escalating Doses of Intradermal Avotermin (Juvista) | Biotech Hunter | Biotech Hunter